Karolinska Institutet and KTH Royal Institute develop improved stem cell method for diabetes reversal
Updated
Updated · SciTechDaily · Apr 25
Karolinska Institutet and KTH Royal Institute develop improved stem cell method for diabetes reversal
8 articles · Updated · SciTechDaily · Apr 25
Researchers in Sweden generated mature, uniform insulin-producing cells from multiple human stem cell lines, successfully reversing diabetes in mice by restoring blood sugar control for several months.
The new technique refines cell culture processes, reduces unwanted cell types, and enables transplanted cells to respond strongly to glucose, addressing previous challenges in stem cell-based diabetes therapies.
This advancement could pave the way for patient-specific treatments and reduce immune rejection risks, supporting ongoing efforts to translate stem cell therapies for type 1 diabetes into clinical practice.
How long until this lab-grown pancreas moves from mice to human trials?
What is the secret within 3D cell clusters that conquers diabetes?
Is this the final step toward a cure without lifelong anti-rejection drugs?
Can this breakthrough be scaled affordably for millions of patients worldwide?
How does this advance change the race against companies like Sana Biotechnology?
Breakthrough in Producing Mature Insulin-Producing Stem Cells Paves Way for Type 1 Diabetes Cure
Overview
In April 2026, Swedish researchers developed a new protocol that produces purer and more mature insulin-producing cells from stem cells, overcoming previous issues of contamination and immaturity. Laboratory tests confirmed these cells respond well to glucose and secrete insulin effectively. When transplanted into the eyes of diabetic mice, the cells integrated with the circulatory system and reversed diabetes by regulating blood sugar. Building on this success, researchers are creating immune protection methods, such as engineered regulatory T cells and gene-edited immune-evasive cells, to enable early-phase human clinical trials starting in 2026. Significant funding, including a $343 million investment from the Novo Nordisk Foundation, supports this promising path toward a stem cell cure for type 1 diabetes.